SELLAS Life Sciences Announces Topline Results From Its Phase 3 REGAL Trial Evaluating Galinpepimut-S In Patients With Acute Myeloid Leukemia Met Primary Endpoint
Benzinga Newsdesk 1 day ago
NewsFDA
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
REGAL trial met its primary endpoint with GPS demonstrating statistically significant and clinically meaningful reduction in risk of death by 41% with median overall survival of 24.0 months versus 14.7 months for best available treatment, and a hazard ratio of 0.59 (p=0.035) -
- Company plans to meet with the U.S. Food and Drug Administration (FDA) while advancing preparations for a Biologics License Application (BLA) submission for GPS -
- SELLAS to host webcast today, November 17, 2026, at 7:45 a.m. Eastern Time -
